Standard treatment for newly diagnosed high grade glioma (Grade 3 or Grade 4) includes surgical removal of as much of the tumor as possible followed by radiation therapy and chemotherapy with temozolomide. Unfortunately, despite these measures, the tumor often recurs and participation in a clinical trial may be recommended.
Tocagen™ is conducting investigational clinical trials of Toca 511 & Toca FC at select neuro-oncology centers in the United States (participating centers are shown in the right hand panel of this page).
A patient may qualify for a Toca 511 & Toca FC study if the patient:
- Has a recurrent high grade glioma (Grade 3 or Grade 4)
- Has had prior surgery, radiation and chemotherapy
- Is at least 18 years of age
In these studies, Toca 511 is given one time by either injection into the brain tumor (Intratumoral Study), into the wall of the resection cavity at the time of tumor removal (Toca 5 Study, Resection Study), or intravenously with a subsequent injection into the wall of the resection cavity at the time of tumor removal (Intravenous Study). After waiting several weeks to allow Toca 511 to spread through the tumor, repeat courses (cycles) of oral Toca FC (extended-release formulation of 5-FC) are taken. In addition to the direct killing of cancer cells, we believe that the immune system is selectively activated by the local tumor killing, with resultant systemic anti-tumor immunity. A schematic of how Toca 511 and 5-FC is designed to work is shown below.
Learn more about Tocagen Clinical Trials:
Brain Cancer (High Grade Glioma)
Toca 511 & Toca FC